Terumo Corporation · TSE:4543
Terumo — Q3 FYE/Mar. 2007 Earnings Presentation
17 slides from Terumo's earnings presentation, March 2007
Slide 1: 3rd Quarter Financial Results for FYE/Mar. 2007
3rd Quarter Financial Results for FYE/Mar. 2007 Results Overview and Topics Terumo Corporation 1
Slide 2: Sales and profits continuing to enjoy double-digit growth
Sales and profits continuing to enjoy double-digit growth (Unit: billion yen) 3Q FYE/Mar. 2006 3Q FYE/Mar. 2007 Rate of change Net Sales 183.6 205.1 11.7% Gross Profit (%) 100.1 (54.5%) 113.2 (55.2%) 13.1% SGA Expenses (%) 61.4 (33.4%) 68.0 (33.2%) 10.7% Operating Income (%) 38.7 (21.1%) 45.2 (22.0%
Slide 3: Net Sales (by product group)
Net Sales (by product group) (Unit: billion yen) +21.6 Consolidated total: 11.7% 205.1 183.6 CV and vascular grafts 33.7 (Growth rate: 18.3%) +5.2 28.5 Interventional products 46.5 +9.9 (Growth rate: 27.0%) 36.6 21.9 +0.5 Home health care products 21.3 (Growth rate: 2.6%) General hospital products +
Slide 4: Net Sales (by Region)
Net Sales (by Region) (Unit: billion yen) Consolidated Net Sales 205.1 +21.6 11.7% (9.5%) 183.6 1 7 .1 +2.5 Asia&Others 16.8% (11.1% ) 1 4 .6 3 8 .0 +9.5 2 8 .5 Americas 33.4% (29.8% ) 2 8 .2 3 4 .8 +6.6 Europe 3.3% (15.2% ) Overseas 26.0% (20.2%) 1 1 2 .3 1 1 5 .3 +3.0 Japan 2.7% Excluding impact o
Slide 5: Gross Profit Margin: 55.2% +0.7pt
Gross Profit Margin: 55.2% +0.7pt compared to previous year Positive factors : +1.6pt Negative factors : ▲0.9pt Effect of production Price decline, etc. increase Shift to higher-profit +0.1 products ▲0.9 +1.5 +0.7pt 5
Slide 6: Details of SGA Expenses
Details of SGA Expenses (Unit: billion yen) 68.0 +6.6 (Increase rate) 61.4 11.6 +0.5 R&D (4.4%) 11.1 6.9 +0.7 Sales promotion and 6.2 5.7 +0.3 advertising (11.6%) 5.4 Logistics (6.3%) 23.6 +3.0 Personnel (14.4%) 20.7 Others (11.3%) 20.1 18.1 +2.0 3Q FYE/Mar. 2006 3Q FYE/Mar. 2007 SGA Expenses rate ▲
Slide 7: Expecting to Achieve the Forecast for Full Fiscal Year
Expecting to Achieve the Forecast for Full Fiscal Year (Unit: billion yen) Increase FYE/Mar. 2006 FYE/Mar. 2007 (forecast) rate Net Sales 247.0 273.0 11% Operating Income (%) 48.3 (19.5%) 57.5 (21.1%) 19% Ordinary Income (%) 48.9 (19.8%) 57.5 (21.1%) 18% Net Income (%) 32.5 (13.1%) 37.0 (13.6%) 14%
Slide 8: Topics
Topics 8
Slide 9: DuraHeart Latest clinical trial data
DuraHeart Latest clinical trial data (as of January 25, 2007) Mean age (Average) 54.5 Mean duration of support (days) 165 No. of patients supported > 6 months 11 （> 12 months） （4） Overall survival (%) 76 Mean days of hospitalisation (days) 45 9
Slide 10: DuraHeart Differences identified in long-term survival
DuraHeart Differences identified in long-term survival Comparison by the Kaplan-Meier Survival Analysis (%) DH (N=29) Comparison group (N=655) 100 Comparison group: LVAD registry, the Transplant Society 90 80 70% 70 Survival rates 60 Early stage deaths mainly change in 50 depend on difference in lon
Slide 11: DuraHeart Left ventricular assist system
DuraHeart Left ventricular assist system "DuraHeart" ■Europe: CE Mark expected in the 4th quarter this fiscal year ■U.S. : Application for clinical trial planned in the next fiscal year ■Japan : Preparation in progress for application for clinical trial 11
Slide 12: Drug-eluting stent Nobori
Drug-eluting stent "Nobori" ■Europe: CE Mark expected in 4th quarter this fiscal year ■Japan : Preparation in progress, application for clinical trial ■Implant of 360 cases completed 12
Slide 13: Sales in Japan now in recovery
Sales in Japan now in recovery Growth Comparison with the same period Comparison rate of the previous year (growth rate) by quarter 7.0% 6.0% 5.0% 4.0% 3.0% 2.0% 1.0% 0.0% -1.0% -2.0% 1Q FYE Mar. 2Q FYE Mar. 3Q FYE Mar. 2007 2007 2007 13
Slide 14: Pharmaceuticals drive the business in Japan
Pharmaceuticals drive the business in Japan ¾ I.V. solution - Standardization and streamlining of products in progress, expanding sales - Good sales of new product with superb risk management functions, "Amigrand" "Amigrand” ¾ Pre-filled syringes - Minofit sales gradually increasing - Good sales of
Slide 15: Sales of diabetes care products continue to grow
Sales of diabetes care products continue to grow ¾ Device for glucose monitoring, "Medisafe Mini" - 22% share in Japan "Medisafe Mini" - Focusing on safety and convenience ¾ Insulin needles, "NanoPass" - Domestic sales gradually increasing - Production capability to be increased in future Reduce pai
Slide 16: Joint Venture with Olympus
Joint Venture with Olympus ¾ Terumo's collagen business joining forces with Olympus' biomaterial and regenerative medicine business "Olympus Terumo Biomaterial Corp." (Established on April 1, 2007) ¾Development of new composite artificial Ceramics element bone substitute material Composite artificia
Slide 17: IR Contact
IR Contact TERUMO Corporation Corporate Communication (IR) Dept. E-mail: [email protected] This document contains forward-looking statements that reflect management’s current views with respect to certain future events and financial performance. Actual results may differ materially from